A polyepitopic CD8+ T-cell response is critical for the control of hepatitis B virus (HBV)
infection. The
HBV X protein (HBx) is a multifunctional
protein that is important for the viral life cycle and for host-virus interactions. The aim of this study was to analyze the immunogenicity and dominance of various
HLA-A*0201-restricted HBx-derived
epitopes. For this purpose, we immunized
HLA-A*0201-transgenic mice with HBx-derived
peptides and
DNA. This is a powerful model for studying the induction of
HLA-A*0201-restricted immune responses in vivo, as these mice possess a cytotoxic T lymphocyte (CTL) repertoire representative of HLA-A2.1 individuals. We used cytotoxic tests and
enzyme-linked
immunosorbent spot (ELISPOT) assays to study the induction of specific cytotoxic and
interferon (IFN)-gamma-secreting T cells. This allowed us to classify the HBx
epitopes according to their T-cell activation capacity. After endogenous processing of the
antigen synthesized in vivo after
DNA-based immunization, we found that the HBx-specific T-cell response is targeted against one
immunodominant epitope. Furthermore, following
peptide immunization, we identified six additional novel subdominant
T-cell epitopes. Inclusion of well-characterized
epitopic sequences of HBx in a new
vaccine for chronic HBV
infections could help to broaden the T-cell response.